FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic - FDA Press Releases

FDA approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults with treatment-resistant depression

from Food and Drug Administration--Press Releases https://ift.tt/2H2JP31
via IFTTT